Jaguar Health (JAGX) Stock

Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Therapeutics has been named "Best Pharmaceuticals Innovator of the Year - Europe" by The European, a quarterly business publication published by CP Media Global Ltd in London. "We are very honored to receive this award," said Massimo Radaelli, PhD, Chief Executive Officer of Napo Therapeutics and President of Jaguar International, "as we continue to be laser-focused on our mission of expanding access to crofelemer in Europe for orphan and rare diseases.

Jaguar Health, Inc. (NASDAQ:JAGX ) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief Scientific Officer Carol Lizak - Chief Financial Officer Operator [Call Starts Abruptly] before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage, which may not make -- achieve scientific objectives or meet changing regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those complicated in such forward-looking statements.

The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial for its cancer supportive care drug crofelemer; results in breast cancer patients accepted for poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS) Jaguar initiated commercial launch in October 2024 for Gelclair ®, the company's third prescription product, in alignment with Jaguar's focus on cancer supportive care Jaguar is initiating two Phase 2 trials in Q4, 2024 and supporting multiple investigator-initiated proof-of-concept studies ("IIT") of crofelemer for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU, and Middle East/North Africa (MENA) regions; results of IITs expected by the end of 2024 and throughout 2025 REMINDER: Jaguar to host investor webcast Wednesday, November 13th at 8:30 a.m. Eastern regarding Q3 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated third-quarter 2024 financial results and provided Company updates.

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS SAN FRANCISCO, CA / ACCESSWIRE / November 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaking abstract about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial, which indicates that crofelemer achieved significant results in this subgroup, has been accepted for a poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS). Patients with breast cancer accounted for the majority of participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Severe mucositis/pharyngitis occurred in 70% of head and neck cancer patients in third-party study SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") has initiated the commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the U.S. "Cancer is chaotic, because patients feel a loss of control - over their life, their treatment, and their supportive care needs," said Catherine Collis, Jaguar's Senior Vice President of Growth Strategy. "Jaguar's mission is to change patients' lives for the better, especially in the area of supportive care for complex disease states like cancer.

SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the OnTarget phase 3 study recently conducted by Jaguar family company Napo Pharmaceuticals, was submitted by the study's primary investigators to a relevant oncology conference for consideration for a presentation. In this study 142 patients with solid tumors received placebo tablets and nearly 75 of them were patients with breast cancer receiving targeted therapies with or without standard chemotherapy.

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the company's Phase 3 OnTarget trial indicate that crofelemer achieved statistical significance in this subgroup. Patients with breast cancer accounted for nearly 180 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Jaguar family company Napo Pharmaceuticals for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.

SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on September 19, 2024 at the MedInvest Biotech & Pharma Investor Conference and participate in one-on-one meetings at the event, which is taking place September 18-19 in New York City. Participation Instructions for Jaguar Health's Presentation at the MedInvest Biotech & Pharma Investor Conference When: Thursday, September 19, 2024 from 9:55 AM Eastern to 10:10 AM Eastern Registration link for presentation: Click Here About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain.

Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Service Dog Month, a time devoted to raising awareness and showing appreciation for the extraordinary work service dogs do every day for the people in their care. "September is National Service Dog Month.